Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 21 entries
Sorted by: Best Match Show Resources per page
Artificial intelligence predicts delirium following cardiac surgery: A case study.

Journal of clinical anesthesia

Fliegenschmidt J, Hulde N, Preising MG, Ruggeri S, Szymanowski R, Meesseman L, Sun H, von Dossow V.
PMID: 34333447
J Clin Anesth. 2021 Dec;75:110473. doi: 10.1016/j.jclinane.2021.110473. Epub 2021 Jul 29.

Delirium is a highly relevant complication of surgical interventions. Current research indicates that despite increased awareness for delirium, it is often overlooked. We implemented an AI-based tool to monitor delirium in cardiac surgery patients in our specialist clinic. This...

Cite
Fliegenschmidt J, Hulde N, Preising MG, et al. Artificial intelligence predicts delirium following cardiac surgery: A case study. J Clin Anesth. 2021;75:110473doi: 10.1016/j.jclinane.2021.110473.
Fliegenschmidt, J., Hulde, N., Preising, M. G., Ruggeri, S., Szymanowski, R., Meesseman, L., Sun, H., & von Dossow, V. (2021). Artificial intelligence predicts delirium following cardiac surgery: A case study. Journal of clinical anesthesia, 75110473. https://doi.org/10.1016/j.jclinane.2021.110473
Fliegenschmidt, Janis, et al. "Artificial intelligence predicts delirium following cardiac surgery: A case study." Journal of clinical anesthesia vol. 75 (2021): 110473. doi: https://doi.org/10.1016/j.jclinane.2021.110473
Fliegenschmidt J, Hulde N, Preising MG, Ruggeri S, Szymanowski R, Meesseman L, Sun H, von Dossow V. Artificial intelligence predicts delirium following cardiac surgery: A case study. J Clin Anesth. 2021 Dec;75:110473. doi: 10.1016/j.jclinane.2021.110473. Epub 2021 Jul 29. PMID: 34333447.
Copy Download .nbib Format: NLM
Clinical practices underlie COVID-19 patient respiratory microbiome composition and its interactions with the host.

Nature communications

Lloréns-Rico V, Gregory AC, Van Weyenbergh J, Jansen S, Van Buyten T, Qian J, Braz M, Menezes SM, Van Mol P, Vanderbeke L, Dooms C, Gunst J, Hermans G, Meersseman P, Wauters E, Neyts J, Lambrechts D, Wauters J, Raes J.
PMID: 34716338
Nat Commun. 2021 Oct 29;12(1):6243. doi: 10.1038/s41467-021-26500-8.

Understanding the pathology of COVID-19 is a global research priority. Early evidence suggests that the respiratory microbiome may be playing a role in disease progression, yet current studies report contradictory results. Here, we examine potential confounders in COVID-19 respiratory...

Cite
Lloréns-Rico V, Gregory AC, Van Weyenbergh J, et al. Clinical practices underlie COVID-19 patient respiratory microbiome composition and its interactions with the host. Nat Commun. 2021;12(1):6243doi: 10.1038/s41467-021-26500-8.
Lloréns-Rico, V., Gregory, A. C., Van Weyenbergh, J., Jansen, S., Van Buyten, T., Qian, J., Braz, M., Menezes, S. M., Van Mol, P., Vanderbeke, L., Dooms, C., Gunst, J., Hermans, G., Meersseman, P., Wauters, E., Neyts, J., Lambrechts, D., Wauters, J., & Raes, J. (2021). Clinical practices underlie COVID-19 patient respiratory microbiome composition and its interactions with the host. Nature communications, 12(1), 6243. https://doi.org/10.1038/s41467-021-26500-8
Lloréns-Rico, Verónica, et al. "Clinical practices underlie COVID-19 patient respiratory microbiome composition and its interactions with the host." Nature communications vol. 12,1 (2021): 6243. doi: https://doi.org/10.1038/s41467-021-26500-8
Lloréns-Rico V, Gregory AC, Van Weyenbergh J, Jansen S, Van Buyten T, Qian J, Braz M, Menezes SM, Van Mol P, Vanderbeke L, Dooms C, Gunst J, Hermans G, Meersseman P, Wauters E, Neyts J, Lambrechts D, Wauters J, Raes J. Clinical practices underlie COVID-19 patient respiratory microbiome composition and its interactions with the host. Nat Commun. 2021 Oct 29;12(1):6243. doi: 10.1038/s41467-021-26500-8. PMID: 34716338; PMCID: PMC8556379.
Copy Download .nbib Format: NLM
Case Report of Gastrointestinal Bleeding in an Adult with Chronic Visceral Acid Sphingomyelinase Deficiency.

Case reports in gastrointestinal medicine

Cassiman D, Libbrecht L, Meersseman W, Wilmer A.
PMID: 31080679
Case Rep Gastrointest Med. 2019 Apr 04;2019:9613457. doi: 10.1155/2019/9613457. eCollection 2019.

INTRODUCTION: Acid sphingomyelinase deficiency (ASMD, also known as Niemann-Pick Type A and Type B disease) is a rare, inherited metabolic disorder. Liver-related issues, including cirrhosis and variceal haemorrhage, are a leading cause of early mortality in individuals with chronic...

Cite
Cassiman D, Libbrecht L, Meersseman W, et al. Case Report of Gastrointestinal Bleeding in an Adult with Chronic Visceral Acid Sphingomyelinase Deficiency. Case Rep Gastrointest Med. 2019;2019:9613457doi: 10.1155/2019/9613457.
Cassiman, D., Libbrecht, L., Meersseman, W., & Wilmer, A. (2019). Case Report of Gastrointestinal Bleeding in an Adult with Chronic Visceral Acid Sphingomyelinase Deficiency. Case reports in gastrointestinal medicine, 20199613457. https://doi.org/10.1155/2019/9613457
Cassiman, David, et al. "Case Report of Gastrointestinal Bleeding in an Adult with Chronic Visceral Acid Sphingomyelinase Deficiency." Case reports in gastrointestinal medicine vol. 2019 (2019): 9613457. doi: https://doi.org/10.1155/2019/9613457
Cassiman D, Libbrecht L, Meersseman W, Wilmer A. Case Report of Gastrointestinal Bleeding in an Adult with Chronic Visceral Acid Sphingomyelinase Deficiency. Case Rep Gastrointest Med. 2019 Apr 04;2019:9613457. doi: 10.1155/2019/9613457. eCollection 2019. PMID: 31080679; PMCID: PMC6475549.
Copy Download .nbib Format: NLM
Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza.

JCI insight

Cambier S, Metzemaekers M, de Carvalho AC, Nooyens A, Jacobs C, Vanderbeke L, Malengier-Devlies B, Gouwy M, Heylen E, Meersseman P, Hermans G, Wauters E, Wilmer A, Schols D, Matthys P, Opdenakker G, Marques RE, Wauters J, Vandooren J, Proost P.
PMID: 34793331
JCI Insight. 2022 Jan 11;7(1). doi: 10.1172/jci.insight.155055.

Neutrophils are recognized as important circulating effector cells in the pathophysiology of severe coronavirus disease 2019 (COVID-19). However, their role within the inflamed lungs is incompletely understood. Here, we collected bronchoalveolar lavage (BAL) fluids and parallel blood samples of...

Cite
Cambier S, Metzemaekers M, de Carvalho AC, et al. Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza. JCI Insight. 2022;7(1)doi: 10.1172/jci.insight.155055.
Cambier, S., Metzemaekers, M., de Carvalho, A. C., Nooyens, A., Jacobs, C., Vanderbeke, L., Malengier-Devlies, B., Gouwy, M., Heylen, E., Meersseman, P., Hermans, G., Wauters, E., Wilmer, A., Schols, D., Matthys, P., Opdenakker, G., Marques, R. E., Wauters, J., Vandooren, J., & Proost, P. (2022). Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza. JCI insight, 7(1), . https://doi.org/10.1172/jci.insight.155055
Cambier, Seppe, et al. "Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza." JCI insight vol. 7,1 (2022). doi: https://doi.org/10.1172/jci.insight.155055
Cambier S, Metzemaekers M, de Carvalho AC, Nooyens A, Jacobs C, Vanderbeke L, Malengier-Devlies B, Gouwy M, Heylen E, Meersseman P, Hermans G, Wauters E, Wilmer A, Schols D, Matthys P, Opdenakker G, Marques RE, Wauters J, Vandooren J, Proost P. Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza. JCI Insight. 2022 Jan 11;7(1). doi: 10.1172/jci.insight.155055. PMID: 34793331.
Copy Download .nbib Format: NLM
Atypical response to bacterial co-infection and persistent neutrophilic broncho-alveolar inflammation distinguish critical COVID-19 from influenza.

JCI insight

Cambier S, Metzemaekers M, Carvalho AC, Nooyens A, Jacobs C, Vanderbeke L, Malengier-Devlies B, Gouwy M, Heylen E, Meersseman P, Hermans G, Wauters E, Wilmer A, Consortium C, Schols D, Matthys P, Opdenakker G, Marques RE, Wauters J, Vandooren J, Proost P.
PMID: 34793331
JCI Insight. 2021 Nov 18; doi: 10.1172/jci.insight.155055. Epub 2021 Nov 18.

Neutrophils are recognized as important circulating effector cells in the pathophysiology of severe coronavirus disease 2019 (COVID-19). However, their role within the inflamed lungs is incompletely understood. Here, we collected broncho-alveolar lavage (BAL) fluids and parallel blood samples of...

Cite
Cambier S, Metzemaekers M, Carvalho AC, et al. Atypical response to bacterial co-infection and persistent neutrophilic broncho-alveolar inflammation distinguish critical COVID-19 from influenza. JCI Insight. 2021;doi: 10.1172/jci.insight.155055.
Cambier, S., Metzemaekers, M., Carvalho, A. C., Nooyens, A., Jacobs, C., Vanderbeke, L., Malengier-Devlies, B., Gouwy, M., Heylen, E., Meersseman, P., Hermans, G., Wauters, E., Wilmer, A., Consortium, C., Schols, D., Matthys, P., Opdenakker, G., Marques, R. E., Wauters, J., Vandooren, J., & Proost, P. (2021). Atypical response to bacterial co-infection and persistent neutrophilic broncho-alveolar inflammation distinguish critical COVID-19 from influenza. JCI insight, . https://doi.org/10.1172/jci.insight.155055
Cambier, Seppe, et al. "Atypical response to bacterial co-infection and persistent neutrophilic broncho-alveolar inflammation distinguish critical COVID-19 from influenza." JCI insight vol. (2021). doi: https://doi.org/10.1172/jci.insight.155055
Cambier S, Metzemaekers M, Carvalho AC, Nooyens A, Jacobs C, Vanderbeke L, Malengier-Devlies B, Gouwy M, Heylen E, Meersseman P, Hermans G, Wauters E, Wilmer A, Consortium C, Schols D, Matthys P, Opdenakker G, Marques RE, Wauters J, Vandooren J, Proost P. Atypical response to bacterial co-infection and persistent neutrophilic broncho-alveolar inflammation distinguish critical COVID-19 from influenza. JCI Insight. 2021 Nov 18; doi: 10.1172/jci.insight.155055. Epub 2021 Nov 18. PMID: 34793331.
Copy Download .nbib Format: NLM
Patents vs patients 1-0: The case of chenodeoxycholic acid.

Journal of inherited metabolic disease

Briké SM, Meersseman W, Cassiman D.
PMID: 34599614
J Inherit Metab Dis. 2021 Oct 02; doi: 10.1002/jimd.12443. Epub 2021 Oct 02.

Profit-driven games with the availability and prices of chenodeoxycholic acid led to the discontinuation of proper treatment for this cerebrotendinous xanthomatosis patient with disastrous consequences to his health.

Cite
Briké SM, Meersseman W, Cassiman D. Patents vs patients 1-0: The case of chenodeoxycholic acid. J Inherit Metab Dis. 2021;doi: 10.1002/jimd.12443.
Briké, S. M., Meersseman, W., & Cassiman, D. (2021). Patents vs patients 1-0: The case of chenodeoxycholic acid. Journal of inherited metabolic disease, . https://doi.org/10.1002/jimd.12443
Briké, Sarah Marie, et al. "Patents vs patients 1-0: The case of chenodeoxycholic acid." Journal of inherited metabolic disease vol. (2021). doi: https://doi.org/10.1002/jimd.12443
Briké SM, Meersseman W, Cassiman D. Patents vs patients 1-0: The case of chenodeoxycholic acid. J Inherit Metab Dis. 2021 Oct 02; doi: 10.1002/jimd.12443. Epub 2021 Oct 02. PMID: 34599614.
Copy Download .nbib Format: NLM
Intensive care management of acute-on-chronic liver failure.

Journal of hepatology

Bernal W, Karvellas C, Saliba F, Saner FH, Meersseman P.
PMID: 34039487
J Hepatol. 2021 Jul;75:S163-S177. doi: 10.1016/j.jhep.2020.10.024.

The syndrome of acute-on-chronic liver failure combines deterioration of liver function in a patient with chronic liver disease, with the development of extrahepatic organ failure and high short-term mortality. Its successful management demands a rapid and coherent response to...

Cite
Bernal W, Karvellas C, Saliba F, et al. Intensive care management of acute-on-chronic liver failure. J Hepatol. 2021;75:S163-S177doi: 10.1016/j.jhep.2020.10.024.
Bernal, W., Karvellas, C., Saliba, F., Saner, F. H., & Meersseman, P. (2021). Intensive care management of acute-on-chronic liver failure. Journal of hepatology, 75S163-S177. https://doi.org/10.1016/j.jhep.2020.10.024
Bernal, William, et al. "Intensive care management of acute-on-chronic liver failure." Journal of hepatology vol. 75 (2021): S163-S177. doi: https://doi.org/10.1016/j.jhep.2020.10.024
Bernal W, Karvellas C, Saliba F, Saner FH, Meersseman P. Intensive care management of acute-on-chronic liver failure. J Hepatol. 2021 Jul;75:S163-S177. doi: 10.1016/j.jhep.2020.10.024. PMID: 34039487.
Copy Download .nbib Format: NLM
Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function.

Infection and drug resistance

Gijsen M, Elkayal O, Annaert P, Van Daele R, Meersseman P, Debaveye Y, Wauters J, Dreesen E, Spriet I.
PMID: 35035223
Infect Drug Resist. 2022 Jan 08;15:53-62. doi: 10.2147/IDR.S343264. eCollection 2022.

PURPOSE: Critically ill patients with preserved or increased renal function have been shown to be at risk of underexposure to meropenem. Although many meropenem population pharmacokinetic (PK) models have been published, there is no large prospective population PK study...

Cite
Gijsen M, Elkayal O, Annaert P, et al. Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function. Infect Drug Resist. 2022;15:53-62doi: 10.2147/IDR.S343264.
Gijsen, M., Elkayal, O., Annaert, P., Van Daele, R., Meersseman, P., Debaveye, Y., Wauters, J., Dreesen, E., & Spriet, I. (2022). Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function. Infection and drug resistance, 1553-62. https://doi.org/10.2147/IDR.S343264
Gijsen, Matthias, et al. "Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function." Infection and drug resistance vol. 15 (2022): 53-62. doi: https://doi.org/10.2147/IDR.S343264
Gijsen M, Elkayal O, Annaert P, Van Daele R, Meersseman P, Debaveye Y, Wauters J, Dreesen E, Spriet I. Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function. Infect Drug Resist. 2022 Jan 08;15:53-62. doi: 10.2147/IDR.S343264. eCollection 2022. PMID: 35035223; PMCID: PMC8754504.
Copy Download .nbib Format: NLM
Porphyria: awareness is the key to diagnosis!.

Acta clinica Belgica

Heymans B, Meersseman W.
PMID: 33938396
Acta Clin Belg. 2021 May 03;1-7. doi: 10.1080/17843286.2021.1918876. Epub 2021 May 03.

Porphyrias are disorders of the haem biosynthesis which are encountered infrequently and which often present themselves atypically as a combination of gastrointestinal, neurologic and/or dermatologic symptoms. Although they are primarily caused by enzyme defects, inheritance patterns are mostly not...

Cite
Heymans B, Meersseman W. Porphyria: awareness is the key to diagnosis!. Acta Clin Belg. 2021;1-7doi: 10.1080/17843286.2021.1918876.
Heymans, B., & Meersseman, W. (2021). Porphyria: awareness is the key to diagnosis!. Acta clinica Belgica, 1-7. https://doi.org/10.1080/17843286.2021.1918876
Heymans, Benjamin, and Meersseman, Wouter. "Porphyria: awareness is the key to diagnosis!." Acta clinica Belgica vol. (2021): 1-7. doi: https://doi.org/10.1080/17843286.2021.1918876
Heymans B, Meersseman W. Porphyria: awareness is the key to diagnosis!. Acta Clin Belg. 2021 May 03;1-7. doi: 10.1080/17843286.2021.1918876. Epub 2021 May 03. PMID: 33938396.
Copy Download .nbib Format: NLM
Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.

Trials

Vanassche T, Engelen MM, Van Thillo Q, Wauters J, Gunst J, Wouters C, Vandenbriele C, Rex S, Liesenborghs L, Wilmer A, Meersseman P, Van den Berghe G, Dauwe D, Verbeke G, Thomeer M, Fivez T, Mesotten D, Ruttens D, Heytens L, Dapper I, Tuyls S, De Tavernier B, Verhamme P.
PMID: 33375932
Trials. 2020 Dec 29;21(1):1033. doi: 10.1186/s13063-020-04991-y.

No abstract available.

Cite
Vanassche T, Engelen MM, Van Thillo Q, et al. Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. Trials. 2020;21(1):1033doi: 10.1186/s13063-020-04991-y.
Vanassche, T., Engelen, M. M., Van Thillo, Q., Wauters, J., Gunst, J., Wouters, C., Vandenbriele, C., Rex, S., Liesenborghs, L., Wilmer, A., Meersseman, P., Van den Berghe, G., Dauwe, D., Verbeke, G., Thomeer, M., Fivez, T., Mesotten, D., Ruttens, D., Heytens, L., Dapper, I., Tuyls, S., De Tavernier, B., Verhamme, P. (2020). Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. Trials, 21(1), 1033. https://doi.org/10.1186/s13063-020-04991-y
Vanassche, T, et al. "Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study." Trials vol. 21,1 (2020): 1033. doi: https://doi.org/10.1186/s13063-020-04991-y
Vanassche T, Engelen MM, Van Thillo Q, Wauters J, Gunst J, Wouters C, Vandenbriele C, Rex S, Liesenborghs L, Wilmer A, Meersseman P, Van den Berghe G, Dauwe D, Verbeke G, Thomeer M, Fivez T, Mesotten D, Ruttens D, Heytens L, Dapper I, Tuyls S, De Tavernier B, Verhamme P. Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. Trials. 2020 Dec 29;21(1):1033. doi: 10.1186/s13063-020-04991-y. PMID: 33375932; PMCID: PMC7770739.
Copy Download .nbib Format: NLM
A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation.

Microorganisms

Van Daele R, Bekkers B, Lindfors M, Broman LM, Schauwvlieghe A, Rijnders B, Hunfeld NGM, Juffermans NP, Taccone FS, Coimbra Sousa CA, Jacquet LM, Laterre PF, Nulens E, Grootaert V, Lyster H, Reed A, Patel B, Meersseman P, Debaveye Y, Wauters J, Vandenbriele C, Spriet I.
PMID: 34361978
Microorganisms. 2021 Jul 20;9(7). doi: 10.3390/microorganisms9071543.

BACKGROUND: Voriconazole is one of the first-line therapies for invasive pulmonary aspergillosis. Drug concentrations might be significantly influenced by the use of extracorporeal membrane oxygenation (ECMO). We aimed to assess the effect of ECMO on voriconazole exposure in a...

Cite
Van Daele R, Bekkers B, Lindfors M, et al. A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation. Microorganisms. 2021;9(7)doi: 10.3390/microorganisms9071543.
Van Daele, R., Bekkers, B., Lindfors, M., Broman, L. M., Schauwvlieghe, A., Rijnders, B., Hunfeld, N. G. M., Juffermans, N. P., Taccone, F. S., Coimbra Sousa, C. A., Jacquet, L. M., Laterre, P. F., Nulens, E., Grootaert, V., Lyster, H., Reed, A., Patel, B., Meersseman, P., Debaveye, Y., Wauters, J., Vandenbriele, C., & Spriet, I. (2021). A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation. Microorganisms, 9(7), . https://doi.org/10.3390/microorganisms9071543
Van Daele, Ruth, et al. "A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation." Microorganisms vol. 9,7 (2021). doi: https://doi.org/10.3390/microorganisms9071543
Van Daele R, Bekkers B, Lindfors M, Broman LM, Schauwvlieghe A, Rijnders B, Hunfeld NGM, Juffermans NP, Taccone FS, Coimbra Sousa CA, Jacquet LM, Laterre PF, Nulens E, Grootaert V, Lyster H, Reed A, Patel B, Meersseman P, Debaveye Y, Wauters J, Vandenbriele C, Spriet I. A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation. Microorganisms. 2021 Jul 20;9(7). doi: 10.3390/microorganisms9071543. PMID: 34361978; PMCID: PMC8303158.
Copy Download .nbib Format: NLM
Liver Fibrosis Associated with Iron Accumulation Due to Long-Term Heme-Arginate Treatment in Acute Intermittent Porphyria: A Case Series.

JIMD reports

Willandt B, Langendonk JG, Biermann K, Meersseman W, D'Heygere F, George C, Verslype C, Monbaliu D, Cassiman D.
PMID: 26093628
JIMD Rep. 2016;25:77-81. doi: 10.1007/8904_2015_458. Epub 2015 Jun 21.

Acute intermittent porphyria (AIP) is an autosomal dominant disorder of heme biosynthesis due to a mutation in the porphobilinogen deaminase gene. The mutation causes a deficiency in the porphobilinogen deaminase enzyme, thereby causing an accumulation of heme precursors (δ-aminolevulinic...

Cite
Willandt B, Langendonk JG, Biermann K, et al. Liver Fibrosis Associated with Iron Accumulation Due to Long-Term Heme-Arginate Treatment in Acute Intermittent Porphyria: A Case Series. JIMD Rep. 2015;25:77-81doi: 10.1007/8904_2015_458.
Willandt, B., Langendonk, J. G., Biermann, K., Meersseman, W., D'Heygere, F., George, C., Verslype, C., Monbaliu, D., & Cassiman, D. (2016). Liver Fibrosis Associated with Iron Accumulation Due to Long-Term Heme-Arginate Treatment in Acute Intermittent Porphyria: A Case Series. JIMD reports, 2577-81. https://doi.org/10.1007/8904_2015_458
Willandt, Barbara, et al. "Liver Fibrosis Associated with Iron Accumulation Due to Long-Term Heme-Arginate Treatment in Acute Intermittent Porphyria: A Case Series." JIMD reports vol. 25 (2016): 77-81. doi: https://doi.org/10.1007/8904_2015_458
Willandt B, Langendonk JG, Biermann K, Meersseman W, D'Heygere F, George C, Verslype C, Monbaliu D, Cassiman D. Liver Fibrosis Associated with Iron Accumulation Due to Long-Term Heme-Arginate Treatment in Acute Intermittent Porphyria: A Case Series. JIMD Rep. 2016;25:77-81. doi: 10.1007/8904_2015_458. Epub 2015 Jun 21. PMID: 26093628; PMCID: PMC5059188.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 21 entries